NICE Withdraws CAR-T Therapy Tecartus from NHS Despite Patient Advocacy Appeals
核心洞察
The National Institute for Health and Care Excellence (NICE) has recommended against continued NHS provision of Tecartus (brexu-cel (搜索)), the only CAR-T cell therapy available for mantle cell lymphoma (搜索) patients.
Real-world NHS data showed median survival of 2.5 years compared to four years in original clinical trials, leading NICE to conclude the treatment underperformed in clinical practice.
Blood Cancer UK, Lymphoma Action (搜索), and Anthony Nolan (搜索) have formally appealed the decision, citing concerns for patients with very limited treatment alternatives.
The National Institute for Health and Care Excellence (NICE) has recommended withdrawing Tecartus, a pioneering CAR-T cell therapy, from NHS services across England and Wales, prompting formal appeals from leading cancer charities who describe the decision as a "backward step for NHS care."
Tecartus (brexu-cel (搜索)), which re-engineers patients' own immune cells to target and destroy cancer, was initially made available through the Cancer Drugs Fund for individuals with relapsed or refractory mantle cell lymphoma (搜索), a rare form of non-Hodgkin lymphoma (搜索) affecting approximately 600 people annually in the UK.
Real-World Performance Gap Drives Decision
NICE's independent committee based its recommendation on nearly five years of real-world NHS data collected through the Cancer Drugs Fund, which revealed significant performance disparities compared to clinical trial results. The treatment demonstrated a median survival of 2.5 years in NHS patients, substantially lower than the four years observed in original trials.
"Our independent committee carefully considered all available evidence, including patient experiences and data from almost five years of real-world NHS use through the Cancer Drugs Fund," a NICE spokesperson stated. "Sadly, this evidence shows the treatment does not work as well in clinical practice as it did in trials."
Patient Advocacy Groups Mount Formal Challenge
Blood Cancer UK, Lymphoma Action (搜索), and the stem cell charity Anthony Nolan (搜索) have jointly submitted a formal appeal, expressing serious concerns about the implications for patients with limited treatment alternatives. The therapy represents the only CAR-T cell treatment available for mantle cell lymphoma (搜索), a blood cancer that impacts white blood cells (搜索) responsible for fighting infection.
Dr. Rubina Ahmed, director of research, policy and services at Blood Cancer UK, emphasized the treatment's critical role: "For some people with mantle cell lymphoma (搜索), whose cancer has come back or hasn't responded to previous treatment, this Car T-cell therapy offers a last hope of a cure."
Emily John, a specialist nurse at Anthony Nolan (搜索), described witnessing the therapy's transformative impact firsthand: "I've seen first-hand how Tecartus has transformed the lives of patients living with mantle cell lymphoma (搜索), offering them a lifeline when other treatment options haven't worked."
Patient Experience Highlights Treatment Impact
Paul Madley, a 66-year-old Cardiff resident diagnosed with stage 4 mantle cell lymphoma (搜索) in 2021, exemplifies the therapy's potential benefits. After experiencing cancer recurrence in July 2024, he received CAR-T cell therapy in autumn 2024 and achieved remission by March 2025.
"By March 2025, I was given the wonderful news that I was in remission and that's where I currently remain," Madley said. "I lead a full and active lifestyle – I have returned to work as a consultant chartered surveyor three to four days a week, walk my dog most mornings, play golf and generally enjoy my life as I did before my illness."
Treatment Continuity and Future Options
NICE has confirmed that patients who have already initiated Tecartus treatment will be permitted to complete their therapy course. The organization is currently evaluating two additional treatments, sonrotoclax and acalabrutinib, which could potentially offer future therapeutic options for this patient population.
Ropinder Gill, chief executive at Lymphoma Action (搜索), reported receiving numerous inquiries from concerned community members: "There is now a lot of distress that this treatment could be removed as an option."
The formal appeal process will now proceed through NICE's established procedures, with the organization stating it welcomes the challenge and will consider all points raised by the advocacy groups.